Related Experiment Video
Updated: Dec 24, 2025
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity
Stanley J Szefler1, Thomas B Casale2, Tmirah Haselkorn3
1Pediatric Asthma Research Program, Breathing Institute, Children's Hospital Colorado, and University of Colorado School of Medicine, Aurora, Colo.
Insights
Omalizumab effectively reduces asthma exacerbations in children. Greater benefits were observed in children with more severe asthma, indicated by lower lung function and higher eosinophil counts.
Area of Science:
- Pediatric Allergy and Immunology
- Respiratory Medicine
- Clinical Pharmacology
Background:
- Childhood asthma severity significantly impairs daily functioning and quality of life.
- Omalizumab is an established treatment for moderate to severe persistent asthma in children aged 6 and older.
- Predicting omalizumab responsiveness in severe pediatric asthma requires further investigation.
Purpose of the Study:
- To evaluate the response to omalizumab treatment in children with moderate to severe persistent asthma.
- To assess treatment efficacy based on various indicators of asthma severity.
- To identify patient subgroups who may experience greater benefits from omalizumab therapy.
Main Methods:
- Post hoc analysis of three randomized placebo-controlled trials (IA05, ICATA, PROSE) involving children aged 6-11 years.
- Stratification of patients based on body mass index, eosinophil count, fractional exhaled nitric oxide, and baseline severity markers (FEV1, hospitalizations, exacerbations).
- Poisson regression analysis to determine exacerbation rate reductions associated with omalizumab treatment across different severity indicators.
Main Results:
- Omalizumab demonstrated a reduction in asthma exacerbations across analyzed subgroups.
- Greater exacerbation rate reductions were observed in children with lower baseline percent predicted FEV1 (<90%), a history of hospitalizations, frequent baseline exacerbations (≥3), and high baseline eosinophil counts (≥300 cells/μL).
- Specific reductions included 36% for low FEV1, 46% for prior hospitalizations, 42% for frequent exacerbations, and 39% for high eosinophil counts.
Conclusions:
- Omalizumab is effective in reducing exacerbations in children with moderate to severe persistent allergic asthma.
- The findings suggest that omalizumab may offer greater therapeutic benefits for children with more severe asthma phenotypes.
- Baseline severity indicators can help predict which children are most likely to respond favorably to omalizumab treatment.
Background:
Greater severity in childhood asthma negatively impacts functioning and quality of life. Omalizumab is effective in children aged 6 years or older with moderate to severe persistent asthma, but predicting responsiveness in severe disease requires further study.
Objective:
To assess response to omalizumab treatment among children using indicators of asthma severity.
Methods:
Post hoc analyses of randomized placebo-controlled studies of omalizumab (Inner-City Anti-IgE Therapy for Asthma [ICATA], IA05, and Preventative Omalizumab or Step-up Therapy for Fall Exacerbations [PROSE]) stratified by body mass index, eosinophil count, fractional exhaled nitric oxide levels, and baseline severity indicators (baseline percent predicted FEV1, previous hospitalizations, asthma exacerbations). Poisson regression analysis examined exacerbation rate reductions for body mass index, biomarkers, and severity indicators.
Results:
Children aged 6 to 11 years in IA05 (N = 576; 56% white, 17% black, 26% other/missing), ICATA (N = 237; 55% black, 43% Hispanic), and PROSE (N = 342; 59% black, 35% Hispanic) were included. Trends indicative of greater exacerbation rate change ([omalizumab - placebo]/placebo) were observed for low baseline lung function (IA05 percent predicted FEV1: <90%, 36% reduction, 95% CI, -53.3 to -13.5; ≥90%, 22% reduction, 95% CI, -52.1 to 27.5), previous hospitalizations (ICATA: 46% reduction with, 95% CI, -69.7 to -3.9; 24% reduction without, 95% CI, -48.1 to 10.3), frequent baseline exacerbations (IA05: ≥3, 42% reduction, 95% CI, -60.4 to -14.1; <3, 20% reduction, 95% CI, -45.2 to -15.9), and high baseline eosinophil count (IA05: ≥300 cells/μL, 39% reduction, 95% CI, -56.4 to -14.7; <300 cells/μL, 5% reduction, 95% CI, -40.6 to 52.1).
Conclusions:
Omalizumab reduces exacerbations in children with moderate to severe persistent allergic asthma, and may provide greater benefit in children with more severe asthma subtypes.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:24Asthma-III: Symptoms and Complications
Classification of Asthma
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Asthma-IV: Nursing Management
First, in...